کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2583177 1130681 2013 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Suppression of Sclerostin and Dickkopf-1 levels in patients with fluorine bone injury
موضوعات مرتبط
علوم زیستی و بیوفناوری علوم محیط زیست بهداشت، سم شناسی و جهش زایی
پیش نمایش صفحه اول مقاله
Suppression of Sclerostin and Dickkopf-1 levels in patients with fluorine bone injury
چکیده انگلیسی

Evidence has been accumulating for the role of Sclerostin and Dickkopf-1 as the antagonists of Wnt/β-Catenin signaling pathway, which suppresses bone formation through inhibiting osteoblastic function. To get deep-inside information about the expression of the antagonists in patients with fluorine bone injury, a case-control study was conducted in two counties in Hubei Province. Urinary and serum fluoride were significantly higher in patients with fluorine bone injury than in healthy controls. Additionally, patients with fluorine bone injury had significantly lower serum Sclerostin and Dickkopf-1 levels compared with healthy controls (P < 0.001). Serum Sclerostin and Dickkopf-1 levels were significantly correlated with serum fluoride in all studied subjects (n = 186). Low Sclerostin and Dickkopf-1 levels were associated with a significantly increased risk of fluorine bone injury. In conclusion, serum Sclerostin and Dickkopf-1 might be used as important markers of bone metabolism change and potential therapeutic targets to treat fluorine bone injury.


► We examined serum fluorine, urinary fluorine, Sclerostin and Dickkopf-1 levels.
► Urinary and serum fluoride increased in patients with fluoride bone injury.
► Serum Sclerostin and Dickkopf-1 levels were suppressed.
► Serum fluoride had negative correlation with serum Sclerostin and Dickkopf-1.
► Low Sclerostin and Dickkopf-1 levels had significant effect on the risk of fluoride bone injury.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Environmental Toxicology and Pharmacology - Volume 35, Issue 3, May 2013, Pages 402–407
نویسندگان
, , , , , , , ,